In 1960, Nisonoff and his collaborators at the Roswell Park Memorial Institute in New York first proposed the original concept of bispecific antibodies (BsAbs). Since then, with the great progress in theRead More…
Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia
Recently, Amgen announced the long-term efficacy of the company’s bispecific antibody Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia (ALL) at the European Hematology Association (EHA) conference. The medianRead More…
Recent Advances in Hot Areas of Bispecific Antibodies Such as PARP Inhibitors
In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy for patients with neurotrophic receptor tyrosine kinase (NTRK)Read More…
TG Therapeutics’s new anti-CD47 and CD19 therapy TG-1801 enters Phase I clinical practice
TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…
The World’s First Single-domain Antibody Drug Cablivi is Approved by FDA in the United States
French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the single-domain antibody (sdAb) drug Cablivi (caplacizumab) combined with plasma exchange and immunosuppressive therapy, for theRead More…
Regeneron’s Lymphoma Bispecific Antibody Drug Achieved 100% Overall Response Rate
In the 2018 American Society of Hematology (ASH) annual meeting, Regeneron, the US biopharmaceutical company, announced new data from Phase I proof-of-concept studies on the bispecific antibody REGN1979 for the treatment ofRead More…
Research and Development of Blinatumomab in B Cell Malignant Tumor
Blinatumomab is a CD19/CD3 bispecific antibody that is the first bispecific T cell engager (BiTE) and the first CD19-specific antibody approved by the U.S. Food and Drug Administration (FDA). As an immunotherapyRead More…
Targeted Killing of Breast Cancer Cells by p95HER2-T Cell Bispecific Antibody
Immunotherapy was positioned as an emerging and even promising treatment for cancer. Today’s new immunotherapeutic agents for different tumor types, whether used alone or in combination, are increasingly becoming one of theRead More…
The World’s First-and-Only Bispecific T Cell Engager Immunotherapy Approved in Japan
Amgen, the United States biotechnology giant, recently announced that the Ministry of Health, Labor and Welfare (MHLW) has approved bispecific T cell engager immunotherapy Blincyto® (blinatumomab) for the treatment of relapsed orRead More…